Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids
OwnerMichel Gilliet, Roberto Lande +1inventors
InventorsMichel Gilliet, Roberto Lande, Yong-Jun Liu
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18.
Claims26
An antibody comprising a human constant region that binds to a marker specific for pDC cell activation by host (self) nucleic acids that may lead to production of pathogenic interferons or for specific blocking of LL-37 induced immune reactivity to self nucleic acids leading to pathogenic type I IFNs.
A molecular inhibitor comprising an oligonucleotide that binds to a marker specific to pathogenic interferon production.
A molecular inhibitor comprising a small molecule that inhibits pathogenic interferon production.
A method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18.
A method for identifying a marker specific to pathogenic interferon production comprising screening a plurality of cells for one or more of LL-37 and hCAP18 and identifying the cells that express one or more of LL-37 and hCAP18.
A composition comprising an LL-37 and a CpG sequence.
A composition comprising an anti-microbial or an anti-tumor vaccine containing DNA and/or RNA and an LL-37.
A method for enhancing the immunogenicity of a DNA and/or RNA therapeutic agent preparation comprising providing to the preparation LL-37, and optionally a CpG sequence.
Dependencies are inferred from the claim text.